Literature DB >> 24976974

Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?

Assunta Sgambato1, Francesca Casaluce1, Paolo Maione1, Antonio Rossi1, Fortunato Ciardiello1, Cesare Gridelli1.   

Abstract

Entities:  

Year:  2014        PMID： 24976974      PMCID： PMC4073354          DOI： 10.3978/j.issn.2072-1439.2014.06.14

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  13 in total

1.  Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Authors:  Roy S Herbst; Karen Kelly; Kari Chansky; Philip C Mack; Wilbur A Franklin; Fred R Hirsch; James N Atkins; Shaker R Dakhil; Kathy S Albain; Edward S Kim; Mary Redman; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

3.  Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Authors:  Edward S Kim; Marcus Neubauer; Allen Cohn; Lee Schwartzberg; Lawrence Garbo; John Caton; Francisco Robert; Craig Reynolds; Terry Katz; Sreeni Chittoor; Lorinda Simms; Scott Saxman
Journal:  Lancet Oncol       Date:  2013-11-12       Impact factor: 41.316

4.  Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.

Authors:  Shadia Jalal; David Waterhouse; Martin J Edelman; Sreenivasa Nattam; Rafat Ansari; Karuna Koneru; Romnee Clark; Arthur Richards; Jingwei Wu; Menggang Yu; Brian Bottema; Angela White; Nasser Hanna
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

5.  A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.

Authors:  Edward S Kim; Ann M Mauer; William N William; Hai T Tran; Diane Liu; Jack J Lee; Paul Windt; Waun K Hong; Everett E Vokes; Roy S Herbst
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

6.  Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

Authors:  R Rosell; G Robinet; A Szczesna; R Ramlau; M Constenla; B C Mennecier; W Pfeifer; K J O'Byrne; T Welte; R Kolb; R Pirker; A Chemaissani; M Perol; M R Ranson; P A Ellis; K Pilz; M Reck
Journal:  Ann Oncol       Date:  2007-10-17       Impact factor: 32.976

7.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

8.  Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.

Authors:  Charles A Butts; David Bodkin; Edward L Middleman; Craig W Englund; David Ellison; Yasmin Alam; Harvey Kreisman; Peter Graze; James Maher; Helen J Ross; Peter M Ellis; William McNulty; Edward Kaplan; Virginie Pautret; Martin R Weber; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2007-12-20       Impact factor: 44.544

9.  Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Authors:  Shirin Khambata-Ford; Christopher T Harbison; Lowell L Hart; Melissa Awad; Li-An Xu; Christine E Horak; Shaker Dakhil; Robert C Hermann; Thomas J Lynch; Martin R Weber
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

10.  Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

Authors:  Thomas J Lynch; Taral Patel; Luke Dreisbach; Michael McCleod; William J Heim; Robert C Hermann; Eugene Paschold; Nicholas O Iannotti; Shaker Dakhil; Steven Gorton; Virginie Pautret; Martin R Weber; Donald Woytowitz
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544
View more
  10 in total

1.  Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways.

Authors:  Lei Zhen; Desheng Fan; Xianghua Yi; Xinming Cao; Dong Chen; Liming Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  Low expression of long noncoding RNA CASC2 indicates a poor prognosis and regulates cell proliferation in non-small cell lung cancer.

Authors:  Xuezhi He; Zhili Liu; Jun Su; Jinsong Yang; Dandan Yin; Liang Han; Wei De; Renhua Guo
Journal:  Tumour Biol       Date:  2016-01-20

3.  Anticancer function of α-solanine in lung adenocarcinoma cells by inducing microRNA-138 expression.

Authors:  Furui Zhang; Rui Yang; Guojun Zhang; Ruirui Cheng; Yong Bai; Huasi Zhao; Xinhua Lu; Hui Li; Shanshan Chen; Juan Li; Shujun Wu; Ping Li; Xiaonan Chen; Qianqian Sun; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2015-12-02

4.  Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer.

Authors:  Ping Li; Juan Li; Rui Yang; Furui Zhang; Huaqi Wang; Heying Chu; Yao Lu; Shaozhi Dun; Yuanyuan Wang; Wenqiao Zang; Yuwen Du; Xiaonan Chen; Guoqiang Zhao; Guojun Zhang
Journal:  Diagn Pathol       Date:  2015-06-09       Impact factor: 2.644

5.  COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.

Authors:  Kowthar Y Salim; Saman Maleki Vareki; Wayne R Danter; James Koropatnick
Journal:  Oncotarget       Date:  2016-07-05

6.  Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells.

Authors:  Katharine D Grugan; Keri Dorn; Stephen W Jarantow; Barbara S Bushey; Jose R Pardinas; Sylvie Laquerre; Sheri L Moores; Mark L Chiu
Journal:  MAbs       Date:  2016-10-27       Impact factor: 5.857

7.  Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.

Authors:  Keunchil Park; Eun Kyung Cho; Maximino Bello; Myung-Ju Ahn; Sumitra Thongprasert; Eun-Kee Song; Victoria Soldatenkova; Henrik Depenbrock; Tarun Puri; Mauro Orlando
Journal:  Cancer Res Treat       Date:  2017-01-06       Impact factor: 4.679

8.  Targeting Cancer Resistance via Multifunctional Gold Nanoparticles.

Authors:  Pedro Pedrosa; M Luísa Corvo; Margarida Ferreira-Silva; Pedro Martins; Manuela Colla Carvalheiro; Pedro M Costa; Carla Martins; L M D R S Martins; Pedro V Baptista; Alexandra R Fernandes
Journal:  Int J Mol Sci       Date:  2019-11-05       Impact factor: 5.923

9.  microRNA-30b inhibits cell invasion and migration through targeting collagen triple helix repeat containing 1 in non-small cell lung cancer.

Authors:  Shanshan Chen; Ping Li; Rui Yang; Ruirui Cheng; Furui Zhang; Yuanyuan Wang; Xiaonan Chen; Qianqian Sun; Wenqiao Zang; Yuwen Du; Guoqiang Zhao; Guojun Zhang
Journal:  Cancer Cell Int       Date:  2015-09-17       Impact factor: 5.722

10.  Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.

Authors:  Ning Tang; Jun Guo; Qianqian Zhang; Yali Wang; Zhehai Wang
Journal:  Oncotarget       Date:  2016-01-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.